PATENT CLAIM ANALYSIS

Application Number: 16047853
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "210210"]

Abstract:
This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.

Claim (Index 27):
The method of  claim 20 , wherein the inhibitor of PI3K\u03b4 is (R)-4-(3-((R)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 119.0
- Percentile: 95.0
- Lexical Diversity: 1.21053
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14680659', '15054474', '14872918', '14193481', '13601349']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7442258543853748
- 35 USC 102 Novelty (BERT): 0.6426018480636478
- Combined Prediction Score: 0.7340634537532021
- Mean Citation Score: 403.438996
- Max Citation Score: 619.9821
- Similarity Product: 551.1733614201307

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test